Bausch Health Companies Inc. (TSX:BHC) – profile & key information

Company Overview - Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company with a global reach, focusing on improving health outcomes through a mix of branded prescription drugs, generic medicines, OTC products, and medtech devices [2][9] - The company operates across therapeutic segments including gastroenterology, ophthalmology, dermatology, neurology, and aesthetic devices, with significant commercial activity in the United States and other international markets [3][20] Product Portfolio - Key products include Trulance and Xifaxan for gastroenterology, ophthalmic products from Bausch + Lomb, and aesthetic devices from Solta Medical, illustrating a broad product mix that helps mitigate market volatility [4][21] - The operational structure supports targeted R&D and regulatory strategies tailored to each market segment, enhancing the company's ability to manage diverse customer needs [20][24] Financial Information - As of 2025, Bausch Health's market capitalization is estimated to be in the low single-digit billions in Canadian dollars, with annual revenue in the multi-billion CAD range [10][18] - The company has a conservative dividend policy, with yield typically modest or not consistently sustained, and earnings per share (EPS) metrics are sensitive to share count changes and restructuring-related expenses [13][19] Corporate History and Leadership - Bausch Health was rebranded in July 2018 to reflect a renewed focus on healthcare products, following a history of acquisitions and restructuring aimed at restoring investor confidence [25][29] - The leadership team emphasizes operational discipline, regulatory compliance, and strategic capital allocation, which are critical for the company's future growth and value creation [31][34] Market Position and Index Membership - Bausch Health is listed on the Toronto Stock Exchange under the ticker BHC and its index membership varies based on market capitalization and liquidity thresholds [35][38] - The company occupies a mid-cap position within the Canadian healthcare sector, making it significant in the pharmaceutical subsectors [42]